Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

NCT07504458 is registered in ClinicalTrials.gov with Quetzal Therapeutics as lead sponsor.

NCT NCT07504458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07504458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
Lead sponsor
Quetzal Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
June 8, 2026
Completion date
December 31, 2030
Enrollment
150 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukaemia, acute promyelocytic leukemia, acute promyelocytic leukemia (apl), acute promyelocytic leukemia with pml-rara, acute promyelocytic leukemia with t(15;17)(q24.1;q21.2); pml-rara